On the same day the lockdowns were announced, March 16, 2020, the deathvaxx was already ready for human consumption. How about that.
March 16th 2020, deathvaxx already perfected for brand new virus, passed animal trials, and ready for human jabs… how’d they do that?
Remember, no drug company or government had ever developed a successful (ie Safe and Effective) coronavirus vaccine. Yet after failing to develop a single vaccine for anything, in the history of the company, Moderna by Fauci whips up the perfect cure for the Rona in five weeks. This is the official narrative. Don’t be a tin foil flat earther.
Monday, March 16, 2020
A Phase 1 clinical trial evaluating an investigational vaccine designed to protect against coronavirus disease 2019 (COVID-19) has begun at Kaiser Permanente Washington Health Research Institute (KPWHRI) in Seattle. The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, is funding the trial. KPWHRI is part of NIAID’s Infectious Diseases Clinical Research Consortium. The open-label trial will enroll 45 healthy adult volunteers ages 18 to 55 years over approximately 6 weeks. The first participant received the investigational vaccine today.
The study is evaluating different doses of the experimental vaccine for safety and its ability to induce an immune response in participants. This is the first of multiple steps in the clinical trial process for evaluating the potential benefit of the vaccine.
The vaccine is called mRNA-1273 and was developed by NIAID scientists and their collaborators at the biotechnology company Moderna, Inc., based in Cambridge, Massachusetts. The Coalition for Epidemic Preparedness Innovations (CEPI) supported the manufacturing of the vaccine candidate for the Phase 1 clinical trial.
“Finding a safe and effective vaccine to prevent infection with SARS-CoV-2 is an urgent public health priority,” said NIAID Director Anthony S. Fauci, M.D. “This Phase 1 study, launched in record speed, is an important first step toward achieving that goal.”